Ann: Phase 2 Synovial Fluid Biomarker Study Update, page-43

It's a salient point, James. PAR aren't so much running this trial to see if Zilosul has DM properties up to 12 months - they are running the trial up to 12 months, in the knowledge that it has DM properties, to show what's required to unlock maximum valuation of the product:



Combined with PARA_006 (a 750-person extension study, which is set to be approved in the same IND application as 002 - fingers crossed) we should have no shortage of evidence of Zilosul's impact on OA over time, to hammer home it's claim as history's first DMOAD for human use.

As an aside, I think if we are to be able to showcase iPPS' results in dogs as part of any submission, this can only enhance the overall case. As we've said many times before, there's no placebo effect in animals. Dogs don't know they've been given an injection of a medical compound designed to have a multi-modal effect on their diagnosed doggy arthritis. They just know that the pains gone, and the stiffness is gone, and they can run and jump again. What a great image to accompany evidence of MOA, and what this drug might do to the lives of human OA sufferers.